drugset / Trial / NCT07415304
A Phase 1 Study of ISM4808 in Healthy Adult Subjects
Phase 1
Not yet recruiting
86 enrolled
TaiGen Biotechnology Co., Ltd.
R&G Pharma Studies Co.,Ltd. · collab
RandomizedParallel-groupDouble-blindBasic science
Summary
This is a Phase I, randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), food effect, and QTc effects of single and multiple ascending oral doses of ISM4808 in healthy adult subjects.
Timeline
- Start
- 2026-02-13
- Primary completion
- 2026-11-30
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ISM4808 | Unknown | — | Oral |
Indications
No indication recorded.